Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Retatrutide (LY3437943) is an agonist of the glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1, and glucagon receptors. Its dose-response relationships with respect to side effects, safety, and efficacy for the treatment of obesity are not known. METHODS: We conducted a phase 2, double-blind, randomized, placebo-controlled trial involving adults who had a body-mass index (BMI, the weight in kilograms divided by the square of the height in meters) of 30 or higher or who had a BMI of 27 to less than 30 plus at least one weight-related condition. Participants were randomly assigned in a 2:1:1:1:1:2:2 ratio to receive subcutaneous retatrutide (1 mg, 4 mg [initial dose, 2 mg], 4 mg [initial dose, 4 mg], 8 mg [initial dose, 2 mg], 8 mg [initial dose, 4 mg], or 12 mg [initial dose, 2 mg]) or placebo once weekly for 48 weeks. The primary end point was the percentage change in body weight from baseline to 24 weeks. Secondary end points included the percentage change in body weight from baseline to 48 weeks and a weight reduction of 5% or more, 10% or more, or 15% or more. Safety was also assessed. RESULTS: We enrolled 338 adults, 51.8% of whom were men. The least-squares mean percentage change in body weight at 24 weeks in the retatrutide groups was -7.2% in the 1-mg group, -12.9% in the combined 4-mg group, -17.3% in the combined 8-mg group, and -17.5% in the 12-mg group, as compared with -1.6% in the placebo group. At 48 weeks, the least-squares mean percentage change in the retatrutide groups was -8.7% in the 1-mg group, -17.1% in the combined 4-mg group, -22.8% in the combined 8-mg group, and -24.2% in the 12-mg group, as compared with -2.1% in the placebo group. At 48 weeks, a weight reduction of 5% or more, 10% or more, and 15% or more had occurred in 92%, 75%, and 60%, respectively, of the participants who received 4 mg of retatrutide; 100%, 91%, and 75% of those who received 8 mg; 100%, 93%, and 83% of those who received 12 mg; and 27%, 9%, and 2% of those who received placebo. The most common adverse events in the retatrutide groups were gastrointestinal; these events were dose-related, were mostly mild to moderate in severity, and were partially mitigated with a lower starting dose (2 mg vs. 4 mg). Dose-dependent increases in heart rate peaked at 24 weeks and declined thereafter. CONCLUSIONS: In adults with obesity, retatrutide treatment for 48 weeks resulted in substantial reductions in body weight. (Funded by Eli Lilly; ClinicalTrials.gov number, NCT04881760.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Retatrutide is the first triple agonist (acting on GLP-1/GIP/glucagon receptors) with published phase 2 data in people with obesity as well as in people with T2D.”
From Triple Agonism Based Therapies for Obesity (2025) · cites this paper as [45]
Experimental — accuracy not yet measuredIn the citing paper
“e24.2 (95% CI, e26.6 to e21.8) in the 12 mg with an ID of 2 mg group as compared with e2.1 (95% CI, e3.5 to e0.7) in the placebo group.”
From Emerging pharmacotherapies for obesity: A systematic review (2025) · cites this paper as Jastreboff et al, 2023
In the citing paper
“Retatrutide 1-12 mg/week over 48 weeks (primary endpoint for bodyweight: 24 weeks) Up to 22•1% (19•3-24•9) with 12 mg/week Up to 0•5% (0•3-0•6) with 8 mg (initial dose 2 mg)/week High drug discontinuation due to adverse events (up to 16% with 12 mg/week); discontinuation for any reason up to 23•5% (with 4 mg/week); weight plateau not reached Jastreboff et al (2023) 138”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [138]
In the citing paper
“In the retatrutide phase 2 trial for people with overweight or obesity (BMI ≥30 kg/m²), or with a BMI of at least 27 kg/m² with one or more weight-related condition, the mean bodyweight reduction at week 48 in the retatrutide (12 mg once-weekly) groups was up to 24•2% (95% CI 21•8-28•6) compared with 2•1% (0•7-3•5) with placebo.138”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [138]
In the citing paper
“However, these resulted in not-so-rare incidents of therapy discontinuation, and their intensity was clearly linked with higher dosages.”
From Retatrutide—A Game Changer in Obesity Pharmacotherapy (2025) · cites this paper as [39]
114 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
The Physical Activity Guidelines for Americans
Piercy, K. L., Troiano, R. P., Ballard, R. M., Carlson, S. A., Fulton, J. E., Galuska, D. A., George, S. M., & Olson, R. D. (2018) · JAMA · doi:10.1001/jama.2018.14854 · Cited by 9,755
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838
Self-citationA Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
Rubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., Lingvay, I., Mosenzon, O., Rosenstock, J., Rubio, M. A., et al. (2021) · JAMA · doi:10.1001/jama.2021.3224 · Cited by 1,444
Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00213-0 · Cited by 1,419
Wadden, T. A., Bailey, T. S., Billings, L. K., Davies, M., Frias, J. P., Koroleva, A., Lingvay, I., O’Neil, P. M., Rubino, D. M., Skovgaard, D., et al. (2021) · JAMA · doi:10.1001/jama.2021.1831 · Cited by 1,114
Self-citationA rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents
Finan, B., Yang, B., Ottaway, N., Smiley, D. L., Ma, T., Clemmensen, C., Chabenne, J., Zhang, L., Habegger, K. M., Fischer, K., et al. (2015) · Nature Medicine · doi:10.1038/nm.3761 · Cited by 645
A new glucagon and GLP-1 co-agonist eliminates obesity in rodents
Day, J. W., Ottaway, N., Patterson, J. T., Gelfanov, V., Smiley, D., Gidda, J., Findeisen, H., Bruemmer, D., Drucker, D. J., Chaudhary, N., et al. (2009) · Nature Chemical Biology · doi:10.1038/nchembio.209 · Cited by 641
Aminian, A., Al-Kurd, A., Wilson, R., Bena, J., Fayazzadeh, H., Singh, T., Albaugh, V. L., Shariff, F. U., Rodriguez, N. A., Jin, J., et al. (2021) · JAMA · doi:10.1001/jama.2021.19569 · Cited by 375
Cited by
Items 601–700 of 1,139
Role of endogenous incretin hormones, GLP-1 and GIP, in cardiovascular physiology
Trivedi, K., & Dolinsky, V. W. (2026) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2025-0163 · Cited by 7
Freschi, M. L., Künstner, A., Huber, G., Stölting, I., Busch, H. S., Hirose, M., & Raasch, W. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1453989 · Cited by 3
White, M. E., & Kushnir, V. M. (2024) · Gastrointestinal Endoscopy Clinics of North America · doi:10.1016/j.giec.2024.06.003 · Cited by 4
Hitaka, K., Sugawara, T., Matsumoto, M., & Nio, Y. (2026) · International Journal of Obesity · doi:10.1038/s41366-026-02025-2 · Cited by 3
“More recently, tirzepatide and retatrutide were studied as novel GLP-1 analogs [19, 20].”
Larsen, A. T., Melander, S. A., Mohamed, K. E., Petersen, E. A., Benmarce, M., Karsdal, M. A., & Henriksen, K. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118388 · Cited by 3
Panunzi, S., Russo, S. L. M. L., Pompa, M., Gaetano, A. D., Verrastro, O., Tuccinardi, D., Guidone, C., Castagneto‐Gissey, L., Casella, G., Mariolo, J. R. C., et al. (2026) · Metabolism · doi:10.1016/j.metabol.2026.156495 · Cited by 5
Cercato, C., Stumpf, M. A. M., Freire, G. N. D. C., Kawahara, E. Z., Fernandes, A. E., de Melo, M. E., & Mancini, M. C. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01842-1 · Cited by 4
“The potency of achieving a weight loss greater than 10–15% is also noticeable [6–8].”
Orforglipron: A Novel Oral GLP-1 Agonist for the Treatment of Obesity and Diabetes
Pillai, A. A., Sharma, A. M., Krayem, H., Frishman, W. H., & Aronow, W. S. (2025) · Cardiology in Review · doi:10.1097/crd.0000000000001139 · Cited by 3
Ramsbacher, N. C. (2024) · Clinical Diabetes · doi:10.2337/cd24-0062 · Cited by 5
Integration of signal transduction pathways in sensory epithelial enteroendocrine cells
Bellampalli, S. S., Joshi, V., Fonar, G., & Beyder, A. (2025) · Molecular Biology of the Cell · doi:10.1091/mbc.e24-03-0143 · Cited by 3
Ashlaw, E. F., Elfers, C., Chichura, K. S., Miranda, I. C., McGivney, A., Chepurny, O. G., Holz, G. G., Mullins, G., den Hartigh, L. J., Liu, Y., et al. (2025) · Metabolism · doi:10.1016/j.metabol.2025.156414 · Cited by 5
“One strategy to achieve this has been to develop incretin-based multiple agonists, such as tirzepatide (TZP), however nausea is reported in up to 40 %–45 % of patients treated [3,4] and the impressive weight loss effects of these drugs is significantly compensated for upon discontinuation [5].”
Glucagon‐Like Peptide‐1 Receptor Agonist‐Based Agents and Body Composition: Filling More Gaps
Dubin, R. L., Sanders, T. N., Schwab, H. M., Heymsfield, S. B., & Greenway, F. L. (2026) · Obesity · doi:10.1002/oby.70212 · Cited by 3
Kanu, C., Wu, Q., Poon, J. L., GOETZ, I. A., Perez‐Nieves, M., Boye, K. S., Martin, C. K., Coşkun, T., & Hartman, M. L. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16662 · Cited by 4
Self-citationIssa, D. (2023) · Gastrointestinal Endoscopy · doi:10.1016/j.gie.2023.08.016 · Cited by 3
Verhoeff, K. K., & Shapiro, A. M. J. (2025) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2025.101414 · Cited by 4
Dysesthesia associated with GLP-1 agonist therapies: data-mining analysis and literature review
Laroche, M., Geniaux, H., & Jardou, M. (2026) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-026-04079-7 · Cited by 9
“In the 3 cases with rechallenge, the same symptoms recurred at the same dose and with a similar dose onset as during the initial episode.”
Abulehia, A., Ayesh, H., Ayesh, O., Jaber, D., Asad, T., Itbaisha, A., Abugharbieh, H., Gharbia, R., Abu‐Hilal, L. H., & Leon, B. G. C. (2026) · Endocrinology, Diabetes & Metabolism · doi:10.1002/edm2.70187 · Cited by 3
GLP-1-based combination strategies for weight loss: Multi-target agents and combination therapies
Wang, X., Lin, R., Sun, Q., Xin, X., & Feng, Q. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108331 · Cited by 2
Bonga, K. N., & Padhan, M. (2026) · Rambam Maimonides Medical Journal · doi:10.5041/rmmj.10565 · Cited by 2
Kukova, L., Munir, K. M., Sayeed, A., & Davis, S. N. (2024) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2024.2401589 · Cited by 2
“Recently published outcomes of phase 2 trials for retatrutide [a GLP-1, GIP, and glucagon receptor agonist] show promising results [114,115].”
InfluentialShould weight loss be the first-line treatment for obstructive sleep apnoea? A pro–con debate
Patel, S. R., & Ryan, S. (2026) · European Respiratory Review · doi:10.1183/16000617.0255-2025 · Cited by 2
“These include drugs combining additional effects, including triple hormone (GLP-1, GIP and glucagon) receptor agonists such as retatrutide [67], and combined GLP-1 and amylin receptor agonists such as amycretin [68] or semaglutide/cagrilintide [69].”
Kanu, C., Clucas, C., Skalicky, A. M., Samuelson, A., GOETZ, I. A., Neff, L. M., Boye, K. S., & Karn, H. (2025) · Advances in Therapy · doi:10.1007/s12325-025-03386-2 · Cited by 3
Windram, M., Lovelock, D. F., Carew, J. M., Krieman, C. G., Hendershot, C. S., & Besheer, J. (2025) · Psychopharmacology · doi:10.1007/s00213-025-06854-3 · Cited by 8
Medikamentöse Adipositastherapie in Deutschland
Blüher, M. (2025) · Die Innere Medizin · doi:10.1007/s00108-025-01897-2 · Cited by 4
Buonanno, S., Gaggiano, C., Baldi, C., Cantarini, L., Frediani, B., & Gentileschi, S. (2026) · Journal of Personalized Medicine · doi:10.3390/jpm16060284 · Cited by 3
Li, C.-H., Huang, Y.-X., Duan, Y., Liu, G.-P., Ai, Z.-W., Ai, Z.-F., Li, J., & Li, S. (2025) · Food & Function · doi:10.1039/d5fo03892h · Cited by 5
Bellido, V., le Roux, C. W., Ekinci, E. I., Bjornstad, P., Frías, J. P., Giblin, K. A., Eyde, S., Park, S. Y., Ferro, J., Johnson, C., et al. (2026) · The Lancet · doi:10.1016/s0140-6736(26)01861-1 · Cited by 8
Self-citationThe complex web of obesity: from genetics to precision medicine
Nair, J. M., & Bharadwaj, D. (2024) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2024.2365785 · Cited by 3
“At a dosage of 12 mg weekly for 48 weeks, it led to 24.2% weight loss in non-diabetic individuals, and in diabetic individuals, it resulted in 16.9% reduction in weight along with 2.16% reduction in HbA1c [125,126].”
InfluentialRega, M., Petraglia, F. M., D’Ursi, L., Buonocore, M., Criscuolo, D., & Santoro, A. (2026) · Clinical bioenergetics · doi:10.3390/clinbioenerg2010005 · Cited by 2
“Retatrutide, which targets three receptors, has also caused notable weight loss in a phase 2 trial [229].”
Bile acids and incretins as modulators of obesity-associated atherosclerosis
Kirsch, A., Gindlhuber, J., Zabini, D., & Osto, E. (2025) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1510148 · Cited by 3
Ray, S., Kapoor, N., Deshpande, N., Chatterjee, S., Kumar, J. S., Tantia, O., Goyal, G., Mukherjee, J. J., & Singh, A. K. (2024) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2024.2330468 · Cited by 3
Glucagon-like Peptide-1 Receptor Agonists: A New Frontier in Treating Alcohol Use Disorder
Oesterle, T., & Ho, M. (2025) · Brain Sciences · doi:10.3390/brainsci15070702 · Cited by 6
Luca, M. D., Modestino, M. R., Alsergani, A. H., Gabriele, M., Galzerano, D., Mallardo, M., Saldamarco, L., Bossone, E., & Cittadini, A. (2026) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2026.103328 · Cited by 4
Borel, A., Ngo, T. H. V., Coumes, S., Pépin, J., Abba, J., Tamisier, R., Tonetti, G., Suzeau, P., Reche, F., & Bailly, S. (2025) · Clinical Nutrition · doi:10.1016/j.clnu.2025.09.022 · Cited by 2
The Global Obesity Epidemic: Epidemiology, Health Burden and Policy Priorities
Henney, A. E., & Wilding, J. P. H. (2026) · European Cardiology Review · doi:10.15420/ecr.2025.84 · Cited by 4
“90,91 Cardiometabolic Protection GLP-1 (+/− GIP) RAs confer sustained cardiometabolic protection.”
Raddatz, D. (2023) · Journal für Gastroenterologische und Hepatologische Erkrankungen · doi:10.1007/s41971-023-00170-3 · Cited by 2
“Somit konnten 48%der Teilnehmer eine Gewichtsreduktion vonmehr als 25% nach 48Wochen erreichten, wobei ein Plateau noch nicht erreicht war und eine weitere Gewichtabnahme bei noch längerer Anwendung möglich erscheint [11].”
BackgroundA Hormone Cell Atlas maps the human endocrine system at cellular resolution
Fei, L., Huang‐Doran, I., Lawler, K., Yu, Y., Pett, J. P., Méndez-Acevedo, K. M., Shah, D., Margalef-Rieres, J., Pohlman, J. S., Çakır, B., et al. (2026) · Yearbook of pediatric endocrinology · doi:10.1126/science.aeb2672 · Cited by 6
Sedrak, P., Verma, R., Verma, M., & Connelly, K. A. (2025) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2025.03.037 · Cited by 6
Innovative approaches to the treatment of obesity: from pharmacotherapy to nanomedicine
Romantsova, T. I. (2024) · Obesity and metabolism · doi:10.14341/omet13184 · Cited by 5
Incretin-based therapies for liver disease
Kotsiliti, E. (2024) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-024-00961-w · Cited by 2
Tratamiento farmacológico de la obesidad. Situación actual y nuevos tratamientos
Pérez, J. S., & Miguel, G. A. (2024) · Atención Primaria · doi:10.1016/j.aprim.2024.103074 · Cited by 8
Renke, G., & Chinellato, L. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27093890 · Cited by 3
“Retatrutide (tri-agonist): In a phase II trial (Eli Lilly, Indianapolis, IN, USA, 2023), retatrutide achieved an average weight reduction of 22% at 48 weeks—the largest ever recorded pharmacologically to date [30].”
Obesity and GEP-NEN: what’s new?
Boschetti, M., Hasballa, I., Patelli, I., Piras, G., & Albertelli, M. (2025) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2025.12.006 · Cited by 3
Key challenges of post-liver transplant weight management
Berković, M. C., Šeša, V., Balen, I., Lai, Q., Silovski, H., & Mrzljak, A. (2024) · World Journal of Transplantation · doi:10.5500/wjt.v14.i4.95033 · Cited by 5
Current status, perceptions, and barriers regarding weight loss approaches in China
Lin, Z., Zhu, H., Si, S., Xu, J., Artime, E., Khare, S., Higgins, V., Leith, A., & Bi, Y. (2025) · Endocrine · doi:10.1007/s12020-025-04315-7 · Cited by 5
“In addition, a phase 3 clinical trial of reta-trutide, a GLP-1, GIP, and glucagon receptor agonist with a weight loss effect of 24.2% at 48 weeks (12 mg) in a phase 2 study [21], is ongoing in China.”
InfluentialPark, C. J., Lee, A. T., & Ou, S. I. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-24-02514 · Cited by 2
Peptide Polyagonists for the Treatment of Nonalcoholic Fatty Liver Disease
Pοlyzos, S. A., Frühbeck, G., & Kiortsis, D. N. (2023) · Current Pharmaceutical Design · doi:10.2174/0113816128279822231211101522 · Cited by 2
Ahmad, Y., Wasan, R., Perchik, J. D., & Nanda, N. C. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15124430 · Cited by 2
“It is presumed that GCG agonism allows for alterations to energy intake and expenditure that aid in weight loss [127].”
GLP-1 RAs: The newest powerhouse in metabolic medicine
Drake, E. S., Marino, A. B., Theroux, J. D., & Roberts, K. (2024) · The Nurse Practitioner · doi:10.1097/01.npr.0000000000000216 · Cited by 2
Kistkins, S., Moser, O., Ankudovičs, V., Bļizņuks, D., Mihailovs, T., Lobanovs, S., Sourij, H., Pfeiffer, A. F. H., & Pīrāgs, V. (2024) · Endocrine Connections · doi:10.1530/ec-23-0529 · Cited by 3
“Recently, retatrutide was demonstrated in obese people to reduce body weight by up to 24.2% over 48 weeks (12).”
BackgroundInfluentialEmerging concepts in obesity management: focus on glucagon receptor agonist combinations
Anderson, S. L. (2025) · Drugs in Context · doi:10.7573/dic.2025-4-8 · Cited by 4
Characterization of Interchanging Incretin Analogs in Clinical Practice: A Descriptive Report
Hvisdas, C., Goode, N., Kim, D. H., Silvey, M. J., & Flood, J. J. (2024) · Endocrine Practice · doi:10.1016/j.eprac.2024.09.117 · Cited by 2
Agarwal, A., & Padwal, R. S. (2025) · Annals of Internal Medicine · doi:10.7326/annals-25-03745-jc · Cited by 2
HIV Treatment and Obesity: What’s New?
Freitas, P., & Ribeiro, S. (2024) · Infectious diseases · doi:10.5772/intechopen.112667 · Cited by 2
Cai, K., Chen, Z., Deng, S., Chen, J., Yu, J., Zhang, X., Jia, W. P., Huang, A., Chen, Y., Xie, Z., et al. (2026) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.5c13513 · Cited by 2
Zhang, J., Xu, H., Dong, Y., Feng, J., & Li, R. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.118024 · Cited by 2
Incretin-based therapy for heart failure with reduced ejection fraction: why we need a trial
Butt, J. H., Solomon, S. D., & McMurray, J. J. V. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf635 · Cited by 3
Kanu, C., Kimel, M., Clucas, C., GOETZ, I. A., Neff, L. M., Boye, K. S., & Karn, H. (2025) · Advances in Therapy · doi:10.1007/s12325-025-03460-9 · Cited by 3
Friedman, A. N., Oultache, I., & Hovey, R. (2026) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2026.03.037 · Cited by 3
Sleep and obesity—known interactions and open questions
Schmickl, C. N., Gomez, R., Sunwoo, B. Y., Mesarwi, O. A., Kumar, A., & Malhotra, A. (2026) · Journal of Clinical Sleep Medicine · doi:10.1007/s44470-026-00130-7 · Cited by 3
Retatrutide-Induced Intractable Diarrhea
Komolafe, O. (2026) · Annals of Internal Medicine Clinical Cases · doi:10.7326/aimcc.2025.1218 · Cited by 2
Incretins for management of obesity and obstructive sleep apnea
Hu, X., Yee, B. J., Phillips, C. L., Chapman, J. L., & Grunstein, R. R. (2025) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2025.2513516 · Cited by 2
“At 48 weeks, the trial found that retatrutide at 1 mg, 4 mg, 8 mg, and 12 mg achieved a mean weight reduction of 8.7%, 17.1%, 22.8%, and 24.2%, respectively, which is significantly higher than placebo [66].”
InfluentialManagement of obesity in advanced chronic liver disease
Caussy, C., & Francque, S. (2026) · JHEP Reports · doi:10.1016/j.jhepr.2026.101749 · Cited by 3
“Importantly, next-generation AOMs, such as dual GLP-1/ glucagon agonists (survodutide) and triple GIP/GLP-1/ glucagon agonists (retatrutide) have shown promising results in both obesity management 113,114 and in MASLD/ MASH 115,116 in phase II RCTs.”
Wang, Y., Feng, Z., & Yu, L. (2025) · The Innovation Medicine · doi:10.59717/j.xinn-med.2025.100150 · Cited by 2
Leite, A. R., Dias, J., Godinho, T., Correia-Chaves, J., Borges‐Canha, M., Lourenço, I. M., Leite-Moreira, A. F., & Neves, J. S. (2024) · Endocrinology Insights · doi:10.1159/000541442 · Cited by 5
Ahmed, I. S., Tapponi, S. L., Manaa, H. M., Soltani, A., Hussein, E. S., Parvaresh, F. A., & Hussain, Z. (2026) · Journal of Obesity · doi:10.1155/jobe/6556057 · Cited by 5
Understanding the interplay between chronic lymphocytic leukemia and type 2 diabetes
Vainer, N., Curovic, V. R., Niemann, C. U., Slager, S. L., & Rotbain, E. C. (2024) · Expert Review of Hematology · doi:10.1080/17474086.2024.2383417 · Cited by 4
A New Epoch in Treating Diseases of the Heart
Purnell, J. Q., & Camacho, S. A. (2024) · Journal of clinical lipidology · doi:10.1016/j.jacl.2024.01.007 · Cited by 2
Amycretin in obesity: Mechanisms, clinical efficacy, and future perspectives
Fu, L., Ding, R., Xu, G., Hu, J., & Yang, P. C. (2026) · Metabolism · doi:10.1016/j.metabol.2026.156594 · Cited by 6
Szostak, B., Kułaga, M., Kasprzak, A., Grzybek, M., Mazur-Lesińska, D., Wielgosz-Biała, S., Tyszkiewicz, K., Łozowski, B., Kasprzak, M., & Wilczyńska, B. (2025) · Prospects in Pharmaceutical Sciences · doi:10.56782/pps.361 · Cited by 3
Exploring the Molecular Pathology of Iatrogenic Amyloidosis
Bonilauri, B. (2024) · Journal of Molecular Pathology · doi:10.3390/jmp5020016 · Cited by 4
“Therefore, with the significant increase in the use of GLP-1-receptor agonist drugs (GLP-1Ra), these cases should be closely studied, although more advanced drugs that only require weekly applications and/or are administered orally are entering the market [70–72].”
BackgroundCardiovascular Risk Reduction With GLP-1 RA Drugs
Pigeyre, M., & Gerstein, H. C. (2026) · Circulation · doi:10.1161/circulationaha.126.079319 · Cited by 4
Pharmacogenetics of incretin-based therapies
Yaluri, A. S., Ürgeová, A., Maršálek, M., Javorský, M., & Tkáč, I. (2025) · Postgraduate Medical Journal · doi:10.1093/postmj/qgaf232 · Cited by 3
The Creative Academic Leader: Six Attributes That Shape Discovery, Integrity, and Impact
Mehra, M. R., VUKIĆEVIĆ, M., & Zuckermann, A. O. (2025) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2025.10.010 · Cited by 2
Cox, L., Turnock, L. A., Akrigg, K., & Piatkowski, T. M. (2026) · Addiction Research & Theory · doi:10.1080/16066359.2026.2671771 · Cited by 2
Obesidad, el papel del gastroenterólogo
Costa, V. A., Escobar, D. C., Kerguelen, A., Rodriguez, J., Rodriguez, A., & Neto, M. G. (2024) · Revista Colombiana de Gastroenterología · doi:10.22516/25007440.1192 · Cited by 2
Zheng, N., 涂龙芳, Xu, P., Chen, R., Lu, J., Dai, W., Lin, Y., Ouyang, J., Qiu, J., Wang, Y., et al. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c03845 · Cited by 2
Incretin Signaling Neighborhoods and Adverse Drug Reactions
Wright, S. C., Lindquist, P., ROSENKILDE, M. M., & Lauschke, V. M. (2025) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-062124-015046 · Cited by 3
Deravi, M., Piszczatoski, C., Phillips, B., Huston, J., & Vascimini, A. (2024) · Journal of Pharmacy Technology · doi:10.1177/87551225241285326 · Cited by 3
“9,20 Lifestyle interventions to the extent exhibited by this study may not be feasible for patients depending on their level of health literacy, access to specialists such as dieticians, and time available for counseling sessions.”
Beyond metabolic benefits: The underexplored immunomodulatory effects of GLP-1/glucagon agonists
van Niekerk, G., Fevery, J., & Dallmeier, K. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.02.025 · Cited by 2
Berry, K. A. Z., Garfield, A., Macias, E., Zarini, S., Bowen, S., Cree‐Green, M., Snell‐Bergeon, J. K., Bodkin, S. G., & Bergman, B. C. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag018 · Cited by 5
Al‐Horani, R. A., Aliter, K. F., & Aliter, H. (2024) · Current Diabetes Reviews · doi:10.2174/0115733998276832231124170324 · Cited by 5
Shokravi, A., Seth, J., & Mancini, G. J. (2026) · Cardiovascular Diabetology · doi:10.1186/s12933-026-03113-3 · Cited by 8
“Beyond tirzepatide, other incretin-based therapies have shown promise, such as retatrutide, a novel triple-hormone receptor agonist that simultaneously activates GLP-1, GIP, and glucagon receptors, with early-phase trials demonstrating profound effects on weight reduction [36].”
Ntelis, S., & Wojeck, B. S. (2025) · Current Hypertension Reports · doi:10.1007/s11906-025-01349-0 · Cited by 1
“In the study of Jastreboff et al. [82 ] 338 adults were randomized to different doses of reta - trutide (1–12 mg per week) and placebo for 48 weeks.”
The emerging implications of GLP-1 receptor agonists in radiation therapy
Reinicke, T., & Dilworth, J. T. (2026) · The Oncologist · doi:10.1093/oncolo/oyag073 · Cited by 1
Top studies of 2023 relevant to primary care
Thomas, B. S., Perry, D., Moe, S. S., et al. (2024) · Canadian Family Physician · doi:10.46747/cfp.7004245 · Cited by 1
GLP-1 Is Not Enough: Can Glucagon Fill the Energy Expenditure Gap?
Beji, S., & Caron, A. (2026) · Neuroendocrinology · doi:10.1159/000550812 · Cited by 1
“In phase 2 trials, retatrutide achieved ~24% mean weight loss at 48 weeks, approaching the magnitude observed with bariatric surgery [19].”
InfluentialInterventions to prevent or treat obesity in adult Indigenous Australians: A systematic review
Lan, N. S. R., Ford, J., Gregory, L., Jones, G., Dwivedi, G., & Yeap, B. B. (2025) · Obesity Research & Clinical Practice · doi:10.1016/j.orcp.2025.04.003 · Cited by 1
Glucagon-Like Peptide-1 Receptor Agonists: Their Potential Role in Prediabetes
Panou, T., Gouveri, E., Popovic, D. S., Papazoglou, D., & Παπάνας, Ν. (2026) · Diabetes Therapy · doi:10.1007/s13300-026-01865-5 · Cited by 2
GLP-1 Receptor Agonist Use in Pregnancy
Druce, I. (2025) · Canadian Diabetes & Endocrinology Today · doi:10.58931/cdet.2025.3139 · Cited by 1
Gonçalves, J., Ferreira, H. U., Menino, J., Meira, I., Ribeiro, S., Moreno, T., Leite, A. R., Ferreira, P., Costa, T., Borges-Canha, M., et al. (2026) · International Journal of Obesity · doi:10.1038/s41366-026-02039-w · Cited by 2
“Despite these limitations, the extended follow-up period and the uniform care provided by a dedicated multidisciplinary team strengthen our conclusions and provide valuable long-term data for the Portuguese population.”
Mondoh, A., Contreras, F., Craig, H. C., Crotty, M., & le Roux, C. W. (2026) · Obesity Pillars · doi:10.1016/j.obpill.2026.100256 · Cited by 3
“…oral semaglutide at obesity-specific doses; CagriSema (cagrilintide + semaglutide); survodutide, a GLP-1/glucagon dual agonist; and retatrutide, a GLP-1/GIP/glucagon triple agonist has demonstrated unprecedented efficacy, with retatrutide achieving nearly 24% weight loss in phase II data [31].”
Cardiovascular Benefits of Glucagon-Like Peptide-1 Receptor Agonists
Tran-Duc, P. N., & Heo, K. (2025) · CardioMetabolic Syndrome Journal · doi:10.51789/cmsj.2025.5.e9 · Cited by 4
Future Perspectives in the Management of Obesity
Garcha, S. C., & Kalra, S. (2025) · Springer eBooks · doi:10.1007/978-981-96-1651-0_6 · Cited by 2
Nicoletti, C. F., Lara, F. V.-O. D., & Martinez, J. A. (2026) · Obesity Medicine · doi:10.1016/j.obmed.2026.100690 · Cited by 2
Incretin therapy and obesity: current and future pharmacologic possibilities
Moss, E., Hawk, K., Lollis, K., & Clements, J. N. (2026) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2025-0151 · Cited by 3
A new era in reducing obesity and the risk of cardiovascular disease events in preeclampsia
Malik, A., & Malik, R. A. (2026) · Journal of Hypertension · doi:10.1097/hjh.0000000000004250 · Cited by 1
Second Generation Anti-Obesity Medications
Chimatapu, S. N., Mittelman, S. D., & Singhal, V. (2024) · Current Pediatrics Reports · doi:10.1007/s40124-024-00326-6 · Cited by 2
Bosy‐Westphal, A., Enderle, J., Norman, K., & Müller, M. J. (2026) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.70334 · Cited by 2
Lee, R. S. M., Seah, J., Baqar, S., Srivastava, P., Levelt, E., Leet, A. S., MacIsaac, A. I., Ekinci, E. I., & MacIsaac, R. J. (2026) · Medicina · doi:10.3390/medicina62050870 · Cited by 2
“…in Adults (TRIUMPH-OUTCOMES) trial aims to explore the CV and renal effects of retatrutide, a triple GLP-1/GIP/GCG agonist, in overweight people with pre-existing ASCVD and/or CKD. Primary outcome measures include the time to the first occurrence of composite endpoints, including HF events [55].”
Metadata
- Authors
- Jastreboff, A. M., Kaplan, L. M., Frías, J. P., Wu, Q., Du, Y., Gurbuz, S., Coskun, T., Haupt, A., Milicevic, Z., & Hartman, M. L.
- Affiliations
- Harvard University (US)
- From the Departments of Medicine (Endocrinology and Metabolism) and Pediatrics (Pediatric Endocrinology), Yale University School of Medicine, New Haven, CT (A.M.J.); the Obesity and Metabolism Institute and Department of Medicine, Harvard Medical School, Boston (L.M.K.); Velocity Clinical Research, Los Angeles (J.P.F.); and Eli Lilly, Indianapolis (Q.W., Y.D., S.G., T.C., A.H., Z.M., M.L.H.).
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-08-10
- Volume
- 389
- Issue
- 6
- Pages
- 514-526
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4382049661
- Cited by
- 1,174
- References
- 28
- Citations by year
- 2026: 399 · 2025: 366 · 2024: 310 · 2023: 96
- FWCI
- 181.67
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- retatrutide, obesity, weight loss, dose-response relationship, adverse events, GLP-1 receptor agonists, GIP receptor agonist, glucagon receptor agonist, weight-related comorbidities, body mass index
- MeSH terms
- Adult, Double-Blind Method, Female, Gastric Inhibitory Polypeptide, Humans, Injections, Subcutaneous, Male, Obesity, Weight Loss, Body Mass Index, Treatment Outcome, Receptors, Glucagon, Anti-Obesity Agents, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.